ACST - アカスティ・ファ―マ (Acasti Pharma Inc.) アカスティ・ファ―マ

 ACSTのチャート


 ACSTの企業情報

symbol ACST
会社名 Acasti Pharma Inc (アカスティ・ファ―マ)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種    医療関連(Health Care)
概要 事業概要 --   アカスティ・ファ―マは、カナダのバイオ医薬品会社。脂質異常症と呼ばれる血中脂質異常や心血管障害の予防と治療法の研究、開発、商業化に従事する。主要製品は高トリグリセリド血症治療薬CaPreやOnemiaなど。それらの製品は、オキアミ油に由来するものである。主にカナダと米国で販売を行う。   Acasti Pharma, Inc. engages in the development and commercialization of pharmaceutical applications of its licensed rights for cardiovascular diseases. It focuses on the research of prescription drugs using omega-3, fatty acids derived from krill oil. The company was founded by Henri Harland on February 1, 2002 and is headquartered in Laval, Canada.
本社所在地 545 Promenade du Centropolis Suite 100 Laval Quebec H7T 0A3 CAN
代表者氏名
代表者役職名
電話番号
設立年月日 37288
市場名 NASDAQ Small Cap
ipoyear ―年
従業員数
url www.acastipharma.com
nasdaq_url https://www.nasdaq.com/symbol/acst
adr_tso
EBITDA EBITDA ー
終値(lastsale) 1.24
時価総額(marketcap) 45483038.8
時価総額 時価総額 ―
売上高 売上高 --
企業価値(EV) 企業価値(EV) ー
当期純利益 当期純利益 --
決算概要 決算概要 --

 ACSTのテクニカル分析


 ACSTのニュース

  Acasti PharmaがTRILOGY 1フェーズ3トライアルを更新 Acasti Pharma Updates on TRILOGY 1 Phase 3 Trial  2019/11/26 16:56:36 Investing News Network
「同社は、CaPreのTRILOGY 1の極めて重要な第3相臨床試験で最後の患者が最後の訪問を完了したと発表しました。
The company announced that the last patient completed their final visit in its TRILOGY 1 pivotal Phase 3 clinical trial of CaPre. The post Acasti Pharma Updates on TRILOGY 1 Phase 3 Trial appeared first on Investing News Network .
   Encode Ideas, L.P. Announces the Initiation of Research Coverage on Acasti Pharma, Inc.  2019/11/25 13:30:00 Yahoo Finance
Dover, Delaware--(Newsfile Corp. - November 25, 2019) - Encode Ideas, L.P. Initiates Research on Acasti Pharma, Inc. (NASDAQ: ACST). The full research publication is available here and available on our website at www.encodelp.com. Encode Ideas is initiating coverage on Acasti Pharma, Inc. as a high-risk
   Acasti Pharma Releases Preliminary Data for CaPre in Diabetic Mice  2019/11/18 23:30:13 Investing News Network
According to the announcement, CaPre demonstrated insulin secretion, which its counterpart metformin is not able to do. The post Acasti Pharma Releases Preliminary Data for CaPre in Diabetic Mice appeared first on Investing News Network .
   Acasti Pharma Announces Publication of CaPre Pharmacokinetics Study in a Leading Peer-Reviewed Journal  2019/11/07 13:30:00 Yahoo Finance
LAVAL, Québec, Nov. 07, 2019 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti or the “Company”) (NASDAQ: ACST – TSX-V: ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre® (omega-3 phospholipid) for the treatment of
   Acasti Pharma to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference  2019/10/01 13:00:00 Yahoo Finance
LAVAL, Québec, Oct. 01, 2019 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti or the “Company”) (NASDAQ: ACST – TSX-V: ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre® (omega-3 phospholipid) for the treatment of
   Acasti Pharma's (ACST) CEO Jan D'Alvise on Q2 2018 Results - Earnings Call Transcript  2018-11-14
Acasti Pharma, Inc. (ACST) Q2 2018 Earnings Conference Call November 14, 2018, 11:00 ET Executives David Waldman - IR Jan D'Alvise - President and CEO Pierre Lemieux - Chief Operating Officer, Chief Scientific Officer and Co-Founder Brian Groach - Chief Commercial Officer Jea…

 関連キーワード  (― 米国株 アカスティ・ファ―マ ACST Acasti Pharma Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)